Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy

References

• Griffin AM, Butow PN, Coates AS, et al. On the receiving end: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189–95
   PubMed Web of Science ®Google Scholar
• Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88–95
   PubMed Web of Science ®Google Scholar
• Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003;1:46–57
   PubMedGoogle Scholar
• Gralla RJ, Osoba D, Kris MG, et al. American Society of Clinical Oncology. Recommendations for the use of antiemetics: Evidence- based, clinical practice guidelines. J Clin Oncol 1999;17:2971
   Google Scholar
• Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:104–8
   PubMed Web of Science ®Google Scholar
• Multinational Association for Supportive Care in Cancer. Available from http://www.mascc [Accessed June 2004]
   Google Scholar
• Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409–22
   Google Scholar
• Gridelli C. 5-HT3-receptor antagonists in the control of delayedonset emesis. Anticancer Res 2003;23:2773–82
   PubMed Web of Science ®Google Scholar
• Kris MG, Gralla RJ, Tyson LB, et al. Controlled delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108–14
   PubMed Web of Science ®Google Scholar
• Moreno I, Rosell R, Abad A, et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992;28A:1344–7
   PubMed Web of Science ®Google Scholar
• Moertel CG, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973;13:283–7
   PubMed Web of Science ®Google Scholar
• Herrstedt J. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Dan Med Bull 1998;45:412–22
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard T, Boesgaard M, et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. NEJM 1993;328:1076–80
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinumbased chemotherapy in patients with cancer. J Clin Oncol 1997;15:1690–6
   PubMed Web of Science ®Google Scholar
• Lebeau B, Depierre A, Giovannini M, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Ann Oncol 1997;8:887–92
   Google Scholar
• Sigsgaard T, Herrstedt J, Andersen LJ, et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 1999;80:412–8
   PubMed Web of Science ®Google Scholar
• Sigsgaard T, Herrstedt J, Christensen P, et al. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer 2000;8:233–7
   PubMed Web of Science ®Google Scholar
• Sigsgaard T, Herrstedt J, Handberg J, et al. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as emetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001;19:2091–7
   PubMed Web of Science ®Google Scholar
• Slimane K, Bethune-Volters A, Chidiac J, et al. A prospective, randomized double-blind double dummy study comparing the efficacy and safety of a new oral formulation of metopimazine (orodispersal tablets metopimazine, OT-MPZ) to ondansetron (Ond) for the control of delayed emesis in patients (pts) receiving moderately to highly emetic chemotherapy (CT). Ann Oncol 2004;15(Suppl 3):218
   PubMedGoogle Scholar
• Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–9
   PubMed Web of Science ®Google Scholar
• Lindley CM, Hirsch JD, O’Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331–40
   PubMedGoogle Scholar
• The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. Clin Oncol 1997;15:124–30
   Web of Science ®Google Scholar
• Tsukada H, Hirose T, Yokoyama A, et al. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001;37:2398–404
   PubMed Web of Science ®Google Scholar
• Israel L, Rodary C. Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy. J Int Med Res 1978;6:235–240
   PubMed Web of Science ®Google Scholar
• Aapro MS, Thuerlimann B, Sessa C, et al. A randomized doubleblind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003;14:291–7
   PubMed Web of Science ®Google Scholar